Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1250 participants.
Also called NCT06260722
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,250 participants
- Sponsor
- Registry
-
NCT06260722
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Canada, Mexico, Puerto Rico
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06260722. Randomized; no masking; primary purpose treatment. Start 2024-02-21 (actual); primary completion 2026-08-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Retatrutide
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06260722- Content hash
13def72c6f555fd803b5ca08b71db4df35f45868a62d2f10f75fdd7eb2fdeb39